The Fort Worth Press - Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

USD -
AED 3.672501
AFN 63.999821
ALL 82.253977
AMD 360.510128
ANG 1.790403
AOA 917.498737
ARS 1552.758602
AUD 1.483977
AWG 1.8025
AZN 1.699803
BAM 1.779545
BBD 2.01413
BDT 124.905034
BGN 1.77347
BHD 0.377331
BIF 3007.507166
BMD 1
BND 1.288858
BOB 11.66537
BRL 5.796998
BSD 1.000059
BTN 93.425596
BWP 13.998644
BYN 3.001178
BYR 19600
BZD 2.011401
CAD 1.429745
CDF 2317.999928
CHF 0.841035
CLF 0.02537
CLP 998.480068
CNY 6.66455
CNH 6.666355
COP 3314.81
CRC 445.481718
CUC 1
CUP 24.000873
CVE 100.328012
CZK 22.18105
DJF 178.098271
DKK 6.79992
DOP 60.559465
DZD 137.08899
EGP 53.689599
ERN 15
ETB 164.140883
EUR 0.90965
FJD 2.296797
FKP 0.758367
GBP 0.75805
GEL 2.595013
GGP 0.758367
GHS 11.73543
GIP 0.758367
GMD 73.502912
GNF 8860.460038
GTQ 7.643069
GYD 209.144677
HKD 7.846205
HNL 26.886001
HRK 6.831965
HTG 131.024035
HUF 333.008502
IDR 18270.5
ILS 3.24803
IMP 0.758367
INR 93.48355
IQD 1516.079284
IRR 1925253.999459
ISK 124.44977
JEP 0.758367
JMD 158.919789
JOD 0.708989
JPY 159.399503
KES 129.999947
KGS 87.449019
KHR 4080.072793
KMF 447.497235
KPW 900.00035
KRW 1336.402706
KWD 0.31172
KYD 0.833458
KZT 444.016797
LAK 22523.690592
LBP 89554.848894
LKR 332.782835
LRD 168.006442
LSL 16.919297
LTL 2.95274
LVL 0.60489
LYD 6.462884
MAD 9.981438
MDL 18.311519
MGA 4549.44565
MKD 56.069019
MMK 2099.8229
MNT 3605.49036
MOP 8.082545
MRU 40.524838
MUR 47.859893
MVR 15.409893
MWK 1734.212921
MXN 18.486875
MYR 4.094503
MZN 63.910141
NAD 16.918528
NGN 1349.369821
NIO 36.80602
NOK 9.625225
NPR 149.481136
NZD 1.81936
OMR 0.384508
PAB 1.000032
PEN 3.415635
PGK 4.499381
PHP 63.6585
PKR 276.505202
PLN 4.00316
PYG 6230.864068
QAR 3.64562
RON 4.865802
RSD 107.022012
RUB 82.04668
RWF 1480.116648
SAR 3.756442
SBD 8.098361
SCR 13.879028
SDG 601.49862
SEK 10.126925
SGD 1.288895
SHP 0.758581
SLE 23.050416
SLL 20969.503664
SOS 571.501363
SRD 37.43798
STD 20697.981008
STN 22.292284
SVC 8.750364
SYP 13002.000337
SZL 16.918877
THB 33.834502
TJS 9.216015
TMT 3.51
TND 3.026264
TOP 2.40776
TRY 50.417602
TTD 6.771395
TWD 32.941978
TZS 2650.003004
UAH 45.33545
UGX 4149.985442
UYU 40.627659
UZS 12019.053598
VES 914.603604
VND 25712.5
VUV 120.845902
WST 2.802705
XAF 596.691317
XAG 0.02097
XAU 0.000259128447
XCD 2.70255
XCG 1.802383
XDR 0.707052
XOF 596.691317
XPF 108.509428
YER 236.503383
ZAR 16.94351
ZMK 9001.198726
ZMW 20.486504
ZWL 321.999592
SSP 5946.953244
MXV 2.073939
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial  for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies -

Text size:

Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic (SÚKL) approved an application for a Phase I clinical trial of an investigational CD123-specific autologous CAR T-cell therapy by the Institute of Hematology and Blood Transfusion (ÚHKT/Eng: IHBT) in Prague for the treatment of relapsed and/or refractory acute myeloid leukemia (AML). UHKT-CAR123-01 utilizes Applied DNA's synthetic DNA, Linea™ DNA, as a critical component in its manufacture.

AML is a hematologic malignancy with a high rate of treatment failure for which current treatment options are often restricted to palliative approaches. Novel emerging methods leveraging advancements in genetic medicines, such as CAR T-cell therapies, can potentially improve outcomes of patients after relapse but have been difficult to establish for clinical use due to high costs and long manufacturing times predominantly attributable to the use of viral vectors.

UHKT-CAR123 seeks to address these issues by generating CD123-specific CAR T-cells in a non-viral workflow utilizing Linea DNA to reduce manufacturing costs and timelines. Preclinical data showed that ÚHKT's Linea DNA-empowered non-viral workflow resulted in the rapid production of substantial and cost-efficient CAR T-cell yields with high potency[1].

"The use of Linea DNA illustrates our innovative approach to finding new and best-in-class treatments for patients with relapsed or refractory AML," stated Dr. Jan Vydra, principal investigator of the UHKT-CAR123 clinical trial.

Added Pavel Otáhal, Ph.D., scientific project leader at ÚHKT, "The Linea DNA platform enables the very rapid abiotic production of expression vectors usable for highly effective electroporation-based CAR-T manufacturing compared to plasmid-based vectors. The decreases in complexities and costs of developing autologous CAR-T technologies offer an innovative approach for the rapid clinical testing of novel types of CAR-T products. This is an incredible milestone for ÚHKT and one that we could not have achieved without the commitment of the Applied DNA team."

Applied DNA CEO Dr. James A. Hayward, said, "We congratulate ÚHKT on their progress into the clinic. Their accomplishment is also a significant milestone for Linea DNA as we look to support additional customers expected to initiate clinical trials in calendar 2025."

About Linea™ DNA

Linea™ DNA is an enzymatically produced, linear DNA manufactured by the Company's proprietary, large-scale polymerase chain reaction ("PCR") based manufacturing platform, the Linea™ DNA platform. As an alternative to plasmid-based DNA, Linea DNA can be used to manufacture of a wide range of nucleic acid-based therapies and in vitro diagnostics, including mRNA therapies, DNA vaccines, cell and gene therapies, and molecular and genetic diagnostic tests.

About Applied DNA Sciences

Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we currently operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.

Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, the unknown future demand for its biotherapeutics and/or diagnostic products and services, the unknown amount of revenues and profits that will result from its Linea IVT and or Linea DNA platforms, the unknown outcome of the IHBT clinical trial, unforeseeable adverse events that could be encountered in the IHBT clinical trial, the fact that there has never been a commercial drug product utilizing the Linea DNA and/or the Linea IVT platform approved for therapeutic use, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events unless otherwise required by law.

Contacts:

Investor Relations contact: Sanjay M. Hurry, 917-733-5573, [email protected]

Program contact: Brian Viscount, 631-240-8877, [email protected]

Web: https://investors.adnas.com/

###

[1] LINEAR DNA PLATFORM FOR THE NON-VIRAL POINT-OF-CARE PRODUCTION OF. . . by Pavel Otáhal. Copyright (C) 2024 MULTILEARNING Group Inc. https://library.ehaweb.org/eha/2024/eha2024-congress/419809/pavel.othal.linear.dna.platform.for.the.non-viral.point-of-care.production.of.html

SOURCE: Applied DNA Sciences, Inc.

T.Harrison--TFWP